Citrine Global crippled by near‑zero cash, heavy related‑party debt and dilution

Citrine Global, Corp (PINK: CTGL) - quick internal and income‑statement snapshot.

What's happening inside
- Cash is essentially depleted: Cash and cash equivalents $4 (amounts in the financials are presented in thousands).
- Balance sheet is strained: Total assets $2,549; total liabilities $5,176; stockholders' deficit $(2,627).
- Heavy related‑party exposure and accruals: Accrued compensation - related parties $2,016; accounts payable - related parties $204; convertible notes (related parties) $2,238.
- Company converted material debt into equity (late 2024 / early 2025), issued large share blocks and warrants - significant dilution risk. Shares outstanding reported at 1,044,074,409 (as of July 30, 2025) and 1,234,185,009 (as of Sept 3, 2025).
- Subsidiary progress and funding: Cannovation (now SkyTech Orion Ltd.) holds 11,687 sqm land asset; subsidiary awarded a government grant of NIS 12.5 million (~USD 3.4m) (notice dated Jan 12, 2025) - potential non‑dilutive project funding.
- Funding runway: working capital deficiency $2,785 and near‑zero cash require reliance on credit facilities, conversions, related‑party support and grants to continue operations.
- Governance/market access issues: company became a delinquent filer in Q2 2024; trading restricted and there is no active market for the shares - liquidity and market‑access risk.

Income statement - positives
- Net loss narrowed sharply: Q1 2024 net loss $252 vs Q1 2023 net loss $852 (all amounts in thousands).
- Financing swing from cost to income: Financing expenses, net = $151 in Q1 2024 vs expense $(335) in Q1 2023 - driven by a $185 fair value gain on the IBOT option (non‑cash).
- Operating costs down year‑over‑year: Operating loss improved to $(403) in Q1 2024 from $(517) in Q1 2023 - cost discipline and changes in R&D spending contributed.

Income statement - negatives
- Still unprofitable: Operating loss $(403) and net loss $(252) in the quarter - no revenue (zero) reported in both Q1 2024 and Q1 2023.
- Much of the improvement is non‑cash or one‑off: the $185 fair value gain on IBOT options is non‑cash and volatile; reliance on such items to improve results is risky.
- R&D and commercialization progress unclear: R&D expense was $0 in Q1 2024 vs $28 in prior year quarter - could reflect delayed activity, not necessarily reduced need for investment.
- High share‑based compensation and dilution: Share‑based compensation $91 in Q1 2024; large option pools outstanding (121,351,132 options outstanding) and recent massive share issuances from convertible conversions and investments materially dilute existing holders.
- Financing & covenant risk: short‑term loans and credit facilities, plus personal guarantees by executives for subsidiary borrowing, increase contingent and reputational risk.

Key numbers & stats (as reported, US$ in thousands unless noted)
- Cash and cash equivalents (Mar 31, 2024): $4.
- Total current assets: $140; Total assets: $2,549.
- Total current liabilities: $2,925; Total liabilities: $5,176.
- Convertible notes: $2,238; Convertible feature (liability) $13.
- Stockholders' deficit: $(2,627).
- Working capital deficiency (Mar 31, 2024): $2,785 (management disclosure).
- Option to purchase IBOT shares (Level 3 fair value): $932 (Mar 31, 2024).
- Operating loss (Q1 2024): $(403) vs $(517) (Q1 2023).
- Financing expenses, net (Q1 2024): $151 (benefit) vs $(335) (Q1 2023).
- Net loss (Q1 2024): $(252) vs $(852) (Q1 2023).
- Loss per share (basic): $(0.00) for Q1 2024; weighted average shares 999,222,964 (Q1 2024).
- Net cash used in operating activities (Q1 2024): $(45); net cash provided by financing activities: $42; net change in cash: $(3).

Bottom line / short action points
- The company is operationally reducing losses but remains highly illiquid and dependent on non‑recurring, non‑cash items and related‑party financing.
- The NIS 12.5m government grant to the subsidiary is a significant positive catalyst if realized and reimbursed, but timing and conditions matter.
- Primary risks: near‑zero cash, working capital deficit, related‑party liabilities, heavy dilution from debt conversions, restricted trading due to delinquent filings.
- For stakeholders: monitor cash inflows (grants, financings), status of uplisting / market reactivation, and any additional dilution or related‑party guarantees. Short term, capital injections or grant reimbursements are the critical near‑term value drivers.

Source: Citrine Global, Corp. Form 10‑Q (unaudited) - condensed consolidated financial statements and MD&A for the quarter ended March 31, 2024 (figures presented in the company's filing; amounts in thousands unless otherwise noted).